Dr. Jeremy Levin, Chairman of the global Biotechnology Innovation Organization (BIO) and Chairman and CEO of OVID Therapeutics, Inc. discusses his perspective on vaccinations and his open letter to members of the biopharmaceutical industry which outlines how public health, and the public’s trust in new medical products, are dependent upon the integrity, transparency and objective assessment of new data as it emerges. He talks about why In the summer of 2020, he gathered 47 top leaders in biopharma to co-author “Biotechnology in the Time of COVID-19: Commentaries from the Front Line” (RosettaBooks).
Dr. Jeremy M. Levin is Chairman and CEO of Ovid Therapeutics Inc (NASDAQ:OVID), a company whose mission is to bring treatment to patients with rare neurological conditions. Dr. Levin is concurrently the chairman of the Biotechnology Innovation Organization (BIO). Prior to founding Ovid, Dr. Levin was president and CEO of Teva Pharmaceutical Industries Ltd., (TLV: TEVA). Dr. Levin was voted as one of the twenty-five most influential biotechnology leaders by Fierce Biotech and one of the top three biotechnology CEOs in 2020 by The Healthcare Technology Report.